Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab dose and frequency reduction optimization in severe allergic asthma
2021-005578-24Phase 4Active
- Sponsor
- Parc de Salut Mar
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in allergic asthma and severe asthma, sponsored by Parc de Salut Mar. Primary endpoint: Exacerbation. Started Feb 2022; status: active.
02
Drugs
omalizumab
03
Conditions
allergic asthmasevere asthma
Beyond the preview
Go deeper on 2021-005578-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005578-24.